MedTrace Logo

"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"

NCT03538717 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 157

Last updated 2022-02-17

Study results available
· View outcomes & findings →

Summary

Retrospective study to collect data from Patients with advanced/metastatic renal cell carcinoma previously treated with Axitinib under standard clinical practice, to describe the clinical profile of the patients with a long response to Axitinib and to try to identify clinical factors which could be related with the long response to Axitinib, through the comparison between long responder patients and a group of refractory patients

Conditions

  • Carcinoma, Renal Cell

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-19
Primary Completion
2019-03-01
Completion
2019-03-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03538717 on ClinicalTrials.gov